PMID- 20553216
OWN - NLM
STAT- MEDLINE
DCOM- 20100930
LR  - 20220310
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Print)
IS  - 1473-7140 (Linking)
VI  - 10
IP  - 6
DP  - 2010 Jun
TI  - Nonhistone protein acetylation as cancer therapy targets.
PG  - 935-54
LID - 10.1586/era.10.62 [doi]
AB  - Acetylation and deacetylation are counteracting, post-translational modifications 
      that affect a large number of histone and nonhistone proteins. The significance 
      of histone acetylation in the modification of chromatin structure and dynamics, 
      and thereby gene transcription regulation, has been well recognized. A steadily 
      growing number of nonhistone proteins have been identified as acetylation targets 
      and reversible lysine acetylation in these proteins plays an important role(s) in 
      the regulation of mRNA stability, protein localization and degradation, and 
      protein-protein and protein-DNA interactions. The recruitment of histone 
      acetyltransferases (HATs) and histone deacetylases (HDACs) to the transcriptional 
      machinery is a key element in the dynamic regulation of genes controlling 
      cellular proliferation, differentiation and apoptosis. Many nonhistone proteins 
      targeted by acetylation are the products of oncogenes or tumor-suppressor genes 
      and are directly involved in tumorigenesis, tumor progression and metastasis. 
      Aberrant activity of HDACs has been documented in several types of cancers and 
      HDAC inhibitors (HDACi) have been employed for therapeutic purposes. Here we 
      review the published literature in this field and provide updated information on 
      the regulation and function of nonhistone protein acetylation. While 
      concentrating on the molecular mechanism and pathways involved in the addition 
      and removal of the acetyl moiety, therapeutic modalities of HDACi are also 
      discussed.
FAU - Singh, Brahma N
AU  - Singh BN
AD  - Department of Mycology & Plant Pathology, Institute of Agricultural Sciences, 
      Banaras Hindu University, Varanasi, India.
FAU - Zhang, Guanghua
AU  - Zhang G
FAU - Hwa, Yi L
AU  - Hwa YL
FAU - Li, Jinping
AU  - Li J
FAU - Dowdy, Sean C
AU  - Dowdy SC
FAU - Jiang, Shi-Wen
AU  - Jiang SW
LA  - eng
GR  - R01 HD041577/HD/NICHD NIH HHS/United States
GR  - R01 HD041577-05/HD/NICHD NIH HHS/United States
GR  - R01 HD041577-06/HD/NICHD NIH HHS/United States
GR  - R01 HD 41577/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Chromosomal Proteins, Non-Histone)
RN  - 0 (Histone Deacetylase Inhibitors)
SB  - IM
MH  - Acetylation
MH  - Chromosomal Proteins, Non-Histone/*metabolism
MH  - Histone Deacetylase Inhibitors/*therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy/*enzymology/pathology
PMC - PMC3273412
MID - NIHMS215094
EDAT- 2010/06/18 06:00
MHDA- 2010/10/01 06:00
PMCR- 2012/02/06
CRDT- 2010/06/18 06:00
PHST- 2010/06/18 06:00 [entrez]
PHST- 2010/06/18 06:00 [pubmed]
PHST- 2010/10/01 06:00 [medline]
PHST- 2012/02/06 00:00 [pmc-release]
AID - 10.1586/era.10.62 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2010 Jun;10(6):935-54. doi: 10.1586/era.10.62.